I-mab Stock News

I-Mab (NASDAQ:IMAB) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and []

I-Mab (NASDAQ:IMAB) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical []

Analysts expect that I-Mab (NASDAQ:IMAB) will post earnings per share (EPS) of ($0.48) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for I-Mabs earnings. The lowest EPS estimate is ($0.95) and the highest is $0.00. The company is expected to announce its next earnings report on Monday, January 1st. On []

I-Mab (NASDAQ: IMAB) has collaborated with Jumpcan Pharmaceutical Group to develop, manufacture, and commercialize eftansomatropin alfa (TJ101) in mainland China. Eftansomatropin alfa is I-Mab's l

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

A year after I-Mab (NASDAQ: IMAB) made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie Inc (NYSE: ABBV), the biotech is reportedly holding talks with big pharma players abou

The Center for Drug Evaluation of China National Medical Products Administration has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial for enoblituzumab in solid tumors.

SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializ

I-Mab (IMAB) CEO Joan Huaqiong Shen on Q2 2021 Results - Earnings Call Transcript

13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJ

SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializa

I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI New majority independent ESG committee to set overall ESG strategies for the Company Women account for two-th

SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializ

SHANGHAI and GAITHERSBURG, Md., Aug. 11, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializ

The FDA has signed off I-Mab (NASDAQ: IMAB) Investigational New Drug (IND) application for Protollin, an Alzheimer's candidate. Brigham and Women's Hospital and Inspirevax granted I-Mab and Nhwa gl